Literature DB >> 8111375

Characterization and localization of the Huntington disease gene product.

A T Hoogeveen1, R Willemsen, N Meyer, K E de Rooij, R A Roos, G J van Ommen, H Galjaard.   

Abstract

The recent identification of the Huntington's disease (HD) gene, enabled us to synthesize oligopeptides corresponding with the carboxy-terminal end of the predicted HD-gene (IT15) product. Immunobiochemcial studies with polyclonal antibodies directed against this synthetic peptide (position 3114-3141) on lymphoblastoid cells from normal individuals and patients with Huntington disease, revealed the presence of a protein (huntingtin) with a molecular mass of approximately 330 kDa. Immunocytochemical studies showed a cytoplasmic localization of huntingtin in various cell types including neurons. In most of the neuronal cells the protein was also present in the nucleus. No difference in molecular mass or intracellular localization was found between normal and mutant cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8111375     DOI: 10.1093/hmg/2.12.2069

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  45 in total

1.  Analysis of the subcellular localization of huntingtin with a set of rabbit polyclonal antibodies in cultured mammalian cells of neuronal origin: comparison with the distribution of huntingtin in Huntington's disease autopsy brain.

Authors:  J C Dorsman; M A Smoor; M L Maat-Schieman; M Bout; S Siesling; S G van Duinen; J J Verschuuren; J T den Dunnen; R A Roos; G J van Ommen
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-06-29       Impact factor: 6.237

Review 2.  Polyglutamine pathogenesis.

Authors:  C A Ross; J D Wood; G Schilling; M F Peters; F C Nucifora; J K Cooper; A H Sharp; R L Margolis; D R Borchelt
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-06-29       Impact factor: 6.237

Review 3.  γ-Glutamylamines and neurodegenerative diseases.

Authors:  Thomas M Jeitner; Kevin Battaile; Arthur J L Cooper
Journal:  Amino Acids       Date:  2012-03-10       Impact factor: 3.520

4.  Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis.

Authors:  Holly B Kordasiewicz; Lisa M Stanek; Edward V Wancewicz; Curt Mazur; Melissa M McAlonis; Kimberly A Pytel; Jonathan W Artates; Andreas Weiss; Seng H Cheng; Lamya S Shihabuddin; Gene Hung; C Frank Bennett; Don W Cleveland
Journal:  Neuron       Date:  2012-06-21       Impact factor: 17.173

5.  The neuroprotectant properties of glutamate antagonists and antiglutamatergic drugs.

Authors:  V Pedersen; W J Schmidt
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

6.  Somatic mosaicism of expanded CAG repeats in brains of patients with dentatorubral-pallidoluysian atrophy: cellular population-dependent dynamics of mitotic instability.

Authors:  H Takano; O Onodera; H Takahashi; S Igarashi; M Yamada; M Oyake; T Ikeuchi; R Koide; H Tanaka; K Iwabuchi; S Tsuji
Journal:  Am J Hum Genet       Date:  1996-06       Impact factor: 11.025

Review 7.  Energy deficit in Huntington disease: why it matters.

Authors:  Fanny Mochel; Ronald G Haller
Journal:  J Clin Invest       Date:  2011-02-01       Impact factor: 14.808

Review 8.  A role for autophagy in Huntington's disease.

Authors:  Katherine R Croce; Ai Yamamoto
Journal:  Neurobiol Dis       Date:  2018-08-24       Impact factor: 5.996

9.  Obsessive-Compulsive Disorder Symptoms in Huntington's Disease: A Case Report.

Authors:  Juan Carlos Molano-Eslava; Angela Iragorri-Cucalón; Gonzalo Ucrós-Rodríguez; Carolina Bonilla-Jácome; Santiago Tovar-Perdomo; David V Herin; Luis Orozco-Cabal
Journal:  Rev Colomb Psiquiatr       Date:  2008-10-01

10.  Expansion of polyglutamine repeat in huntingtin leads to abnormal protein interactions involving calmodulin.

Authors:  J Bao; A H Sharp; M V Wagster; M Becher; G Schilling; C A Ross; V L Dawson; T M Dawson
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-14       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.